FINVASIA Group Announces Acquisition of ActTrader
FINVASIA Group announced today that it has acquired ActTrader Technologies (formerly ActForex) , a pioneer in building financial technology products for over 20 years.
ActTrader was among the world's first "Fintech" companies, well before the buzzword "FinTech" got glamorized. From building the first ever online retail forex trading application back in 2000 to launching the first ever WAP based mobile trading app in 2004, they've grown to build disruptive multi-asset financial technology products that have been trusted by millions of traders worldwide.
ActTrader has a strong heritage as a Fintech solution provider, drawing on 20+ years of operational excellence. It was founded in year 2000 in United States of America and has served almost over 2 million retail traders in over 100 countries. The company has processed over $400 trillion in transaction volume and has acted as the core technology provider to some of the largest financial institutions in the world.
FINVASIA Group is a multi-disciplinary, multinational organization that owns multiple brands in the financial services, fintech, blockchain and technology sectors. Finvasia, along with its subsidiaries and sister concerns, is registered with a gamut of regulatory bodies across the world in various capacities. They have been the torch bearer for introducing commission free investment ecosystem forcing established brokers to offer commission free trading services. Recently, Finvasia acquired Fxview, a Cyprus-based financial services company, to expand its presence in the European market.
"FINVASIA believes in the democratization of the financial system and believes that technology can lead this change," said Sarvjeet Singh, Managing Director of FINVASIA Group. "Uniting our companies will allow us to drive new innovations and create fintech solutions that not only address today's requirements but are also flexible enough to meet tomorrow’s technological advances.”
Together, they envisage to build the next generation of the blockchain and AI based trading applications, a unique social trading platform, robust risk management and liquidity management solutions, variety of plug-ins and business intelligence tools that will challenge industry standards and extend the frontier of Fintech industry. This deal brings together two major Fintech players under one umbrella.
Effective immediately, ActTrader will become a subsidiary under the FINVASIA Group, with Ilya Sorokin continuing as the CEO and all current management and associates remaining in place.
Founder and CEO of ActTrader Technologies, Ilya Sorokin stated, " This acquisition broadens our footprint and strengthens our ability to serve new clients, well and long into the future. As we continue to grow and expand, the ability to provide our clients with innovative next-gen financial technology products is a significant step in our journey."
About ActTrader
ActTrader has been at the forefront of the fintech industry since the launch of its flagship trading application – ActTrader™ (formerly ActForex). From its beginnings in 2000, it has offered superior technology solutions and has grown to build provide multi-asset financial technology products that have been trusted by millions of traders and hundreds of brokers worldwide.
Its broad portfolio of end-to-end trading technology products has helped FX Brokers, ECN Venues and financial institutions transform their trading operations.
Know more: https://acttrader.com/
About FINVASIA Group
FINVASIA is a multi-disciplinary, multinational organization that invests in technology-oriented businesses and products. It is registered with a gamut of regulatory bodies across the world in various capacities. Finvasia (along with its subsidiaries and sister concerns) is registered with SEC, USA (152771), CYSEC, Cyprus (367/18), FCA, UK (850138), BaFin, Germany (157125), ACPR, France (85051), CONSOB, Italy (5151), CNVM, Spain (4892), Finanstilsynet, Norway (FT00118545)
In India, Finvasia is registered with Reserve Bank of India as an NBFC, National Stock Exchange of India as Professional Clearing member (M51912), Bombay Stock Exchange (4043), Multi Commodity Exchange of India (55135) and NCDEX as Trading Member (01259), Association of Mutual Funds of India (103331) and CDSL as Depository Participant (12084300).
Know more: https://finvasia.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210719005554/en/
Contact information
Media
Ms. Sandeep Samra
media@finvaisa.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Making Science Unveils ‘AWAKE’: The AI Venture Studio Industrialising Startup Creation and AI-First Innovative Solutions23.12.2025 20:51:00 CET | Press Release
Making Science, the global digital acceleration consultancy, today announced the launch of AWAKE Venture Studio. This "AI-first" model represents a new era in systematic innovation, designed to identify, prototype, and scale both internal proprietary solutions and independent AI-native startups with global reach. The launch of AWAKE is motivated by the significant efficiency gains of orders of magnitude that Making Science has already achieved through the internal integration of AI. By applying these methods, the firm has achieved a 2x acceleration in tech feature development reducing time in the deployment of AI Agents. This model has already proven its commercial and innovative power through the acceleration of startups like ad-machina, which has multiplied its value by 10 since joining the Making Science ecosystem. These proven benchmarks serve as the technical foundation for AWAKE’s two interconnected engines, which formalise this efficiency into a repeatable manufacturing process
FDA Clears First Extended Depth of Focus Contact Lens for Presbyopia23.12.2025 18:07:00 CET | Press Release
The Cataltheia Group and its U.S. subsidiary, Bruno Vision Care LLC, a leader in eye health innovation, today announced that the U.S. Food and Drug Administration (FDA) has cleared the first and only Daily Disposable Soft (Hydrophilic) Contact Lens for Presbyopia utilizing patented Extended Depth of Focus (EDOF) optical design technology, enabling commercial distribution in the United States. Deseyne® delivers smooth, continuous focus across near, intermediate, and distance vision, providing clear, natural vision without compromise. This performance is enabled by Cataltheia’s patented hyper-refractive central zone, engineered to precisely redirect light in a controlled manner. The result is a clear clinical advantage over the only other available contact lens option for presbyopia, multifocal lenses, which rely on multiple optical zones and often require prolonged visual and cognitive adaptation. “We are proud to offer the first contact lens solution for the world’s aging population th
Aramco Awards SLB Long-Term Contract to Support Kingdom’s Unconventional Gas Production Growth23.12.2025 14:58:00 CET | Press Release
Global technology company SLB (NYSE: SLB) has been awarded a five-year contract by Aramco to provide stimulation services for its unconventional gas fields. This award is part of a broader multi-billion contract, supporting one of the largest unconventional gas development programs globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251223074948/en/ The contract encompasses advanced stimulation, well intervention, frac automation, and digital solutions, which are important to unlocking the potential of Saudi Arabia’s unconventional gas resources. The contract encompasses advanced stimulation, well intervention, frac automation, and digital solutions, which are important to unlocking the potential of Saudi Arabia’s unconventional gas resources — a cornerstone of the Kingdom’s strategy to diversify its energy portfolio and support the global energy transition. “This agreement is an important step forward in Aramco’s effor
Tabelog, Japan's Largest (*1) Restaurant Search and Reservation Service, Launches Multilingual App for International Visitors23.12.2025 14:00:00 CET | Press Release
Tabelog (https://tabelog.com/en/), Japan's largest restaurant search and reservation service operated by Kakaku.com, Inc., launched its multilingual smartphone application (iOS/Android) for international travelers on Monday, November 17, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251221963753/en/ The Tabelog Multilingual App for International Travelers — Japan's Largest Restaurant Search and Reservation Service With approximately 100 million monthly users(*3), Tabelog is Japan's premier service widely used by Japanese locals for daily restaurant discovery. Its database is unrivaled domestically, featuring information on approximately 890,000 establishments nationwide and over 85 million reviews and photos(*4). Unlike global map services or travel sites, Tabelog is built on "authentic ratings and reviews from local Japanese users," enabling travelers to discover truly exceptional restaurants beloved by locals — not
BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference23.12.2025 12:01:00 CET | Press Release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, with a presentation at 7:30 am PST. Live webcasts of these events can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com, https://hkexir.beonemedicines.com, https://sseir.beonemedicines.com. Archived replays will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company based in Switzerland that is discovering and developing innovative treatments that are more accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of nearly 12,000 colleagues spanning six continents, the Company is committed to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom